In RIP1-deficient Jurkat cells reconstituted with wild-type RIP1, 30 μM Necrostatin-1 suppressed induced necroptotic death. The S161E and F162E variants markedly reduced this inhibition, providing cellular evidence for the RIP1 target assignment. [1]
Necrostatin-1 did not rescue MTT viability in primary rat aortic smooth muscle cells exposed for 24 h to MI-2 or erastin at the tested 10 μM Nec-1 concentration. Ferrostatin-1 and deferoxamine rescued viability in parallel. The paper identifies its Nec-1 reagent as Adooq A11973. [3]
RIP1 autophosphorylation inhibition and biochemical controls
Biochemical assay · Immunoprecipitated human RIP1 from HEK293T or Jurkat cells; recombinant human RIP1 as an additional direct-inhibition check [1]
Nec-1 inhibited RIP1 autophosphorylation. Kinase-inactive K45M, RIP1-deficient cells, protein-loading controls and the less active demethylated analogue supported assignment of the assay signal and compound effect. Recombinant RIP1 was also inhibited.
Literature-Reported Treatment Conditions
- Treatment concentration
- Figure 1c: 1, 10 and 100 μM; Figure 1e: 3 and 30 μM; recombinant assay Figure 2d: 30 and 100 μM
- Exposure duration
- 15-min inhibitor preincubation; 30-min kinase reaction
- Method
- Radiolabelled ATP autophosphorylation assay; SDS-PAGE and autoradiography
- Vehicle
- 3% DMSO in the kinase assay
- Reported limits
- No new IC50 is calculated; the SI dose-response material supporting the text-reported potency was not acquired.
Methods and source locations
Compound reported in the paper: Necrostatin-1; Compound label in the paper: 1
Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.
Results, Nec-1 is a RIP1 kinase inhibitor in vitro; Figures 1b–e and 2d–e; Chemical compounds and In vitro kinase assay
RIP1 autophosphorylation: Autoradiography with parallel RIP1 immunoblot controls — Figures 1b–e, 2d–e and corresponding Results
Cellular RIP1 target validation with T-loop mutants
Cell-based study · RIP1-deficient human Jurkat cells reconstituted with wild-type RIP1 or S161A, S161E and F162E variants [1]
Nec-1 suppressed induced death in cells reconstituted with wild-type RIP1, whereas S161E and F162E markedly attenuated inhibition. Equal-expression controls support cellular target assignment. Mutants still required the receptor stimulus to induce death.
Literature-Reported Treatment Conditions
- Treatment concentration
- 30 μM Nec-1
- Exposure duration
- 24-h death-induction assay after 48-h recovery from reconstitution
- Method
- Flow cytometry of GFP-positive, propidium-iodide-negative cells
- Co-treatment
- Agonistic Fas antibody, cycloheximide and zVAD-fmk used to induce necroptosis; CHX + zVAD without Fas was a control.
- Reported limits
- Cellular vehicle fraction is not specified for this comparison. Co-stimulus doses are not transcribed because the retained manuscript has problematic unit typography.
Methods and source locations
Compound reported in the paper: Necrostatin-1; Compound label in the paper: 1
Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.
Results, RIP1 T-loop controls inhibition by Nec-1; Figure 3e and accompanying immunoblots; RIP1 reconstitution in RIP1-deficient Jurkat cells
Cell death with wild-type versus mutant RIP1, with and without Nec-1: FACS viability analysis; RIP1/tubulin immunoblots for expression controls — Figure 3e caption, plot and Results paragraph following Figure 3
IDO activity reveals an additional target of parent Nec-1
Biochemical assay · Purified recombinant human indoleamine 2,3-dioxygenase (IDO), with L-tryptophan substrate [2]
Nec-1 and Nec-1i inhibited IDO activity, whereas Nec-1s did not in the tested range. The 1-methyltryptophan comparator also inhibited IDO. Thus the parent compound cannot be treated as exclusively RIPK1-directed.
Literature-Reported Treatment Conditions
- Treatment concentration
- Three-fold serial dilutions from 100 μM to 1.69 nM
- Exposure duration
- 60-min enzymatic reaction at 37 °C
- Method
- Kynurenine colorimetric endpoint at 490 nm
- Co-treatment
- 100 μM L-tryptophan substrate
- Reported limits
- Vehicle fraction and replicate-number semantics for Figure 4a are not specified in its caption or IDO Methods. No fitted EC50 value is transcribed.
Methods and source locations
Compound reported in the paper: Necrostatin-1; Compound label in the paper: Nec-1
Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.
Results, Nec-1 and Nec-1i, but not Nec-1s, inhibit IDO enzyme activity; Figure 4a; IDO enzymatic assay; Cells, cytokines and reagents
Human IDO enzyme activity: Colorimetric measurement of kynurenine formation — Figure 4a and IDO enzymatic assay
Nec-1 fails to rescue viability in two ferroptosis-associated SMC conditions
Cell-based study · Primary rat aortic smooth muscle cells from Sprague-Dawley rats [3]
Nec-1 did not rescue the loss of MTT viability induced by MI-2 or erastin. Ferrostatin-1 and deferoxamine rescued viability in the same comparison. This is a model-specific negative result, not evidence of a general absence of Nec-1 activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM Nec-1
- Exposure duration
- 24 h
- Method
- Co-treatment; MTT viability assay
- Co-treatment
- MI-2 1 μM or erastin 5 μM; parallel comparator treatments included Fer-1 5 μM, DFO 100 μM, Z-VAD-fmk 25 μM and Z-YVAD-fmk 10 μM.
- Reported limits
- Exact vehicle composition/final concentration for this cell comparison is not specified in the selected text. No exact viability percentage is inferred from the bars.
Methods and source locations
Compound reported in the paper: Necrostatin-1; Compound label in the paper: Nec-1
Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.
Results, Treatment with MI-2 induces ferroptotic cell death in aortic SMCs; Figure 1B–C; Reagents and Antibodies; Cell culture; MTT assay; Statistical analysis
MTT viability after MI-2 or erastin, with or without cell-death inhibitors: MTT assay, absorbance at 595 nm — Figure 1B–C with caption; first Results subsection; Statistical analysis